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 Abstract 
An analytical method comprised of automated solid phase extraction and determination using 
gas chromatography electron capture mass spectrometry has been developed for the 
determination of 12 polybrominated diphenyl ethers (PBDEs), 26 polychlorinated biphenyls 
(PCBs), two organochlorine compounds (OCs) and two brominated phenols in human serum. 
The analytes are extracted using a sorbent of polystyrene-divinylbenzene and an additional 
clean-up is performed on a sulphuric acid silica column to remove lipids. 
 
The method has been validated by spiking horse serum at five levels in the range of 1.2-120 
pg PBDEs/g serum, (12-1200 pg BDE-209/g serum), 1.2-120 pg pentabromophenol (PeBP)/g 
serum, 2.4-240 pg tetrabromobisphenol-A (TBBP-A)/g serum and 3-300 pg PCBs/g serum. 
Different internal standards were evaluated for the PBDEs. The accuracy given as recovery 
relative to internal standards, was from 64-150% with relative standard deviations (RSD) 
ranging from 0.6-56% for the PBDEs. The mean accuracy was 95% and the mean RSD 6.9%. 
The accuracy for the PCBs was in the range of 29-127% with RSD in the range of 0.3-77%, 
and with mean accuracy and RSD of 99% and 8.7% respectively. The two OCs 
hexachlorobenzene and octachlorostyrene had accuracies in the range of 62-104% with RSD 
in the range of 3.2-15%, the mean accuracy was 93% and the mean RSD 7.5%. The accuracy 
for the determination of PeBP and TBBP-A were in the range of 77-132% with RSD from 
4.5-24%, the mean accuracy and RSD was 109% and 15% respectively. In summary, the 
overall accuracy and RSD was about 98% and 8.4% respectively. Estimated limits of 
detection (LOD, signal to noise ratio =3) were in the range of 0.2-1.8 pg/g serum for the 
PBDEs and phenols, the PCBs and OCs had LODs in the range of 0.1-56 pg/g serum. The 
method linearity was determined by plotting the concentration of persistent organic pollutants 
found in the spiked validation samples against the concentration added. Correlation 
coefficients were in the range of 0.9981-1.0000. 
 
The validated method has been used to investigate the levels of PBDEs and PCBs in pooled 
serum samples from men (age 40-50 years) sampled in the time period 1977 to 2003, and in 
pooled serum samples from different age groups sampled in 2002 (all from the general 
Norwegian population). The sum of seven PBDE congeners (IUPAC No. 28, 47, 99, 100, 153, 
154 and 183) has increased from 1977 (0.61 ng/g lipids) to 1998 (4.85 ng/g lipids). From 
1999 to 2003 the concentration of PBDEs seems to have stabilized. However, the congener 
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 BDE-153 was found to increase throughout the entire period. On the other hand the sum of 
five PCBs (IUPAC No. 101, 118, 138, 153 and 180) have decreased steadily from 1977 (665 
ng/g lipids) to 2003 (176 ng/g lipids). A comparison was made between the main congeners 
from PCBs and PBDEs, and it was found that the level of CB-153 was about 46 times higher 
than the level of BDE-47 in the serum pool from 2003.  
In samples from 2002 an increase with age was observed for the PCBs. The highest levels 
were observed in the age group >60 years where the sum of five PCBs were 308 ng/g lipids 
and 353 ng/g lipids for women and men, respectively. For the PBDEs the exact opposite trend 
was observed, with the highest levels in the lowest age group (0-4 years), where the sum of 
seven PBDEs was 10.4 ng/g lipids. TBBP-A and BDE-209 were detected in almost all 
samples, but no similar trends to that seen for the PBDEs and PCBs were observed for these 
compounds. 
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1. Introduction 
Persistent organic pollutants (POPs) such as brominated flame retardants (BFRs) and 
polychlorinated biphenyls (PCBs) are now ubiquitous environmental pollutants. The fact that 
these compounds are persistent means that there is a risk that they remain in an organism or 
its environment for a long time which may cause long time exposure. To which degree the 
organic compounds bioaccumulate depends on their solubility in lipids (fats, oils etc.). 
Halogenation of an organic compound reduces its solubility in water and increases its 
solubility in lipids. 
 
Flame retardants (FR) are chemicals that are added to materials during or after manufacture, 
to prevent or reduce the development of a fire. Brominated flame retardants (BFRs) represent 
39% of the worldwide market of flame retardants [1]. Other flame retardants include: 
chlorinated, phosphorous-containing, nitrogen-containing and inorganic flame retardants. 
BFRs are considered to be highly efficient as FRs and economically advantageous both 
regarding production and use.  
 
Worldwide, the total production of flame retardants was estimated to be 600 000 tonnes in 
1992 [2]. The total market demand of brominated flame retardants in 2001 was 203 790 
tonnes, where tetrabromobisphenol-A (TBBP-A) is produced in the largest amounts (119 700 
tonnes), hexabromocyclododecane (HBCD) in 16 700 tonnes and Polybrominated diphenyl 
ethers (PBDEs) in 67 390 tonnes [1]. 
 
There is no domestic production of BFRs in Norway. Accordingly, all BFRs in use are 
imported, as part of flame retarded products or as the chemical itself. 
 
PBDEs are a class of chemicals with the general structure shown in Figure 1. There are 
theoretically 209 PBDE congeners, with one to ten bromine substituents. The congeners are 
numbered from 1 to 209 using the system already existing for PCBs [3], instead of using the 
standard IUPAC nomenclature. 
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Figure1. The general structure of the PBDEs. 
 
PBDEs are lipophilic substances with log KOW of approximately 4-9. For example 2,2’,4,4’-
tetrabromodiphenyl ether (BDE-47) has an estimated log KOW  of 6.8 while the 
heptabrominated congener, BDE-183 has a log KOW of 8.3 [4]. 
 
PBDEs are commercially available as three products, two of which are mixtures of several 
congeners. The so-called penta product contains BDE-47, BDE-99, BDE-100, BDE-153 and 
BDE-154. The octa product contains several hexa-to nona-brominated congeners, and the 
deca product is almost entirely composed of BDE-209 [5]. In Norway the use of penta- and 
octa-BDE was prohibited from 1st July, 2004 [6]. Risk assessments are also being made for 
deca-BDE. 
 
In addition to the PBDEs, several brominated phenolic compounds have been used as flame 
retardants. TBBP-A is the most widely used of these compounds, 2,4,6-tribromophenol 
(TriPB) and pentabromophenol (PeBP) are used to a lesser extent (Figure 2). The phenolic 
BFRs differ from the other BFRs by its hydroxyl groups, which makes them weak acids. 
TBBP-A has proposed log KOW 4.5-5.3, and are thus more soluble in water than the PBDEs 
[7]. 
 9 
Chapter 1  Introduction 
Br
Br Br
Br
CH3
CH3
OHHO
TBBP-A
Br Br
Br
Br
Br
OH
PeBP
BrBr
Br
OH
TriBP
 
Figure 2. Structures of brominated phenolic compounds. 
 
Flame retardants may be either chemically bound to (reactive) or mixed with (additive) 
polymeric materials. TBBP-A is used both reactively (90%) and additively, while the PBDEs 
are only used additively due to the lack of binding sites in the molecules. The primary use of 
TBBP-A is as a reactive intermediate in the manufacture of flame-retarded epoxy and 
polycarbonate resins, accounting for approximately 90% of all TBBP-A used. A principal use 
of TBBP-A epoxy resins is in printed circuit boards. PBDEs are incorporated in acrylonitrile-
butadiene-styrene (ABS), high-impact polystyrene (HIPS), flexible polyurethane foams and 
textile coatings. TriBP and PeBP are used in epoxy resins, phenolic resins and as 
intermediates for polyester resins [7]. These different types of flame retarded polymer 
products are present in a number of consumer products, such as computers, household 
appliances, electronics and TV-sets. PBDEs are also incorporated into products as paints, 
circuit boards, floor mats, carpets and furniture’s. 
 
PCBs shown in Figure 3, have been used commercially since 1930 as dielectric and heat-
exchange fluids and in a variety of other applications [8]. As for the PBDEs, 209 congeners 
are possible, but only 130 are likely to occur in commercial products [8]. In recent years, the 
production of PCBs have been phased out [8]. Current sources of PCB release include 
volatilization from landfills, sewage sludge, spills, dredge spoils and improper (or illegal) 
disposal. The PCBs have log kOWs in the range of 4.5-8.2 with the most chlorinated 
compounds having the highest values. 
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Figure 3. General structure of PCBs. 
 
For humans the main exposure to POPs is through the diet, especially from intake of fatty 
food of animal origin such as fatty fish. Exposure through air might also show out to be an 
important exposure path for the PBDEs [9].  
 
A large number of human samples have been analyzed for BFRs and PCBs. PCBs and 
PBDEs have been found in blood [10-12], adipose tissue [13;14], and in breast milk [15-17]. 
A study of PBDEs in breast milk from Swedish women show an increase in the PBDE levels 
from 1972 to 1998, after 1998 the levels decreased up to year 2001 [18]. In serum increasing 
levels of PBDEs have been reported [19], while the levels of PCBs have been reported to 
decrease over the years [20;21]. The levels of PBDEs and PCBs in humans and the 
environment have been reviewed [8;22-24]. BFRs have been studied in blood samples 
collected from people in different occupational settings [25;26]. Several PBDEs and TBBP-A 
have also been detected in indoor air at a computer dismantling plant, in rooms containing 
computers and other electrical equipment and at a factory for assembly of circuit boards [27]. 
TriBP has been detected in exhaust from vehicles using leaded gasoline [28]. PBDEs, TBBP-
A and TriBP have also been detected in laboratory air [29]. 
 
PCBs, TBBP-A and PBDEs have also been found in sewage sludge and sediments from a 
number of locations [30-32]. In a study near a Swedish plastics industry using TBBP-A, 
higher levels were found in sediment samples collected downstream than upstream, 
indicating that the plastics industry was the source for these substances [33].  
 
One of the first reports on PBDEs in the environment were published 1981 where these 
compounds were detected in fish from Sweden [34]. The fish was collected from the Viskan-
Klosterfjorden water system, and the dominating congeners found was tetra-BDE followed by 
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penta and hexa-BDE. Now PBDEs and PCBs are frequently detected in biota such as in fish 
[35-38], bird eggs [39-41], marine and terrestrial mammals and mussels [42]. 
 
It has been shown that the acute toxicity of TBBP-A and PBDEs is low [5;7]. Limited data 
are available on the toxicity of PBDEs and TBBP-A in humans. In exposure studies of TBBP-
A and deca-BDE no evidence for skin irritation or sensitization was found [5;7]. Skin raches 
have been reported after acute exposure to PCBs [8]. Several PBDEs and PCBs have been 
found to interact with the aryl hydrocarbon (Ah) receptor, mainly as an antagonists, but also 
as agonists [43]. Estrogenic and antiestrogenic activity of several PBDEs and TBBP-A have 
also been reported [44]. In the investigation of nevrotoxic effects of PCBs, PBDEs and 
TBBP-A it was found that mice neonatally exposed to BDE-47, BDE-99 and several PCB 
congeners displayed behavioural changes [45]. Exposure of TBBP-A in the same dose range 
as the PBDEs did not cause any significant changes in behavioural variables investigated. 
PCBs and PBDEs have been shown to effect the thyroid hormone system [46;47]. Thus both 
PCBs and PBDEs have the potential to cause negative effects on human health. 
 
Analytical methods used for determination of PBDEs and PCBs are very similar. The 
separation from biological and environmental matrix is typically performed by extraction 
with organic solvents as in liquid-liquid extraction (LLE) or more recently by solid-phase 
extraction (SPE) [12;48]. Chromatography (e.g. gel permeation, silica gel, floricil, activated 
carbon) is often used to remove matrix components. Lipids can be removed by destructive 
methods such as treatment with concentrated sulphuric acid, or by non-destructive methods 
such as gel permeation. PCBs are usually extracted from blood or serum by solvent extraction 
techniques using hexane, benzene or mixed solvents such as hexane/ethyl ether [49]. BFR 
have been extracted with 2-propanol/hexane, methylene chloride, hexane, formic acid/2-
propanol/water, and hexane/methyl t-butyl ether [49]. Polystyrene-divinylbenzene (PS-DVB) 
based SPE columns have successfully been used for the extraction of BFRs from breast milk 
and serum [48]. The separation and quantification of BFRs and PCBs are most often 
accomplished by gas chromatographic (GC) techniques. Long capillary columns are normally 
used, but the higher brominated PBDEs have longer retention times and are often separated 
on shorter columns. The most common approach for identification and quantification is to use 
electron capture detection (ECD) or mass spectrometric (MS) techniques, such as electron 
ionization (EI) or electron capture negative ionization (ECNI), or to use high resolution mass 
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spectrometry (HRMS). The most frequently used injection techniques are splitless and on-
column injection [50]. 
 
The main objective of this study was to develop a fast, selective and sensitive method for 
determination of halogenated organic pollutants in human serum, by modifying a previously 
described method based on SPE and on-column lipid decomposition [12;51], and transferring 
it to an automated unit. The second objective was to use this method to study the temporal 
trends and the role of age of POPs in pooled serum samples from the general Norwegian 
population. 
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2.   Experimental 
 
2.1  Materials and reagents 
2,4,4´-Tribromodiphenyl ether (BDE-28), 3,4,4´-tribromodiphenyl ether (BDE-37), 2,2´,4,4´-
tetrabromodiphenyl ether (BDE-47), 2,2´,3,4,4´-pentabromodiphenyl ether (BDE-85), 
2,2´,4,4´,5-pentabromodiphenyl ether (BDE-99), 2,3´,4,4´,6-pentabromodiphenyl ether (BDE-
119), 2,2´,4,4´,5,5´-hexabromodiphenyl ether (BDE-153), 2,2´,4,4´,5,6´-hexabromodipenyl 
ether (BDE-154), 2,2´,3,4,4´,5,6-heptabromodiphenyl ether (BDE-181), 2,2´,3,4,4´,5´,6-
heptabromodipenyl ether (BDE-183), 2,2´,3,3´,4,4´,5,5´,6,6´-decabromodiphenyl ether (BDE-
209), 13C-2,4,4´-trichlorobipenyl (CB-28), 13C-2,2´,5,5´-tetrachlorobiphenyl (CB-52), 13C- 
2,2´,4,5,5´-pentachlorobiphenyl (CB-101), 13C-2´,3,4,4´,5-pentachlorobipenyl (CB-123), 13C-
2,3´,4,4´,5-pentachlorobiphenyl (CB-118), 13C-2,3,4,4´,5-pentachlorobiphenyl (CB-114), 13C-
2,2´,4,4´,5,5´-hexachlorobipenyl (CB-153), 13C-2,3,3´,4,4´-pentachlorobiphenyl (CB-105), 
13C-2,2´,3,4,4´,5´-hexachlorobiphenyl (CB-138), 13C-2,3´,4,4´,5,5´-hexachlorobiphenyl (CB-
167), 13C-2,2´,3,4,4´,5,5´-heptachlorobiphenyl (CB-180), 13C-2,3,3´,4,4´,5-
hexachlorobiphenyl (CB-156), 13C-2,3,3´,4,4´,5´-hexachlorobiphenyl (CB-157), 13C-
2,2´,3,3´,4,4´,5-heptachlorobiphenyl (CB-170), 13C-2,3,3´,4,4´,5,5´-heptachlorobiphenyl (CB-
189), 13C-2,2´,3,3´,4,4´,5,5´-octachlorobiphenyl (CB-194), 13C-2,2´,3,3´,4,4´,5,5´,6,6´-
decachlorobiphenyl (CB-209), hexachlorobenzene (HCB), 13C-hexachlorobenzene and 
octachlorostyrene (OCS) and tetrabromobisphenol-A (TBBP-A) were obtained from CIL 
(Andover, MA). 2,3,3´,4,4´,5-hexabromodiphenyl ether (BDE-156), 3,3´,4,4´-
tetrabromodiphenyl ether (BDE-77), 2,2´,4,4´,6-pentabromodiphenyl ether (BDE-100) 
 and 13C-2,2´,3,3´,4,4´,5,5´,6,6´-deca bromodiphenyl ether (BDE-209) were purchased from 
Wellington Laboratories (Guelph, Ontario, Canada). 2,2´,5-tribromodiphenyl ether (BDE-18), 
2,2´,4,6´-tetrabromodiphenyl ether (BDE-51), 2,2´,4,5´,6-pentabromodiphenyl ether (BDE-
103), 2,2´,3,4,4´,5´-hexabromodiphenyl (BDE-138), 2,2´,5-trichlorobiphenyl (CB-18), 2,4,4´-
trichlorobipenyl (CB-28), 2,2´,5,5´-tetrachlorobiphenyl (CB-52), 2,4,4´,5-tetrachlorobiphenyl 
(CB-74), 2,3´,4,4´-tetrachlorobipenyl (CB-66), 3,4,4´,5-tetrachlorobiphenyl (CB-81), 
2,2´,4,4´,5-pentachlorobiphenyl (CB-99), 2,2´,4,5,5´-pentachlorobiphenyl (CB-101), 
2,3,3´,4,4´-pentachlorobiphenyl (CB-105), 2,3,3´,4´,6-pentachlorobipheny (CB-110), 
2,3,4,4´,5-pentachlorobiphenyl (CB-114), 2,3´,4,4´,5-pentachlorobiphenyl (CB-118), 
2´,3,4,4´,5-pentachlorobipenyl (CB-123), 2,2´,3,3´,4,4´-hexachlorobiphenyl (CB-128), 
2,2´,3,4,4´,5´-hexachlorobiphenyl (CB-138), 2,2´,4,4´,5,5´-hexachlorobipenyl (CB-153), 
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2,3,3´,4,4´,5-hexachlorobiphenyl (CB-156), 2,3,3´,4,4´,5´-hexachlorobiphenyl (CB-157), 
2,3´,4,4´,5,5´-hexachlorobiphenyl (CB-167), 2,2´,3,3´,4,4´,5-heptachlorobiphenyl (CB-170), 
2,2´,3,4,4´,5,5´-heptachlorobiphenyl (CB-180), 2,2´,3,4,4´,5´,6-heptachlorobiphenyl (CB-
183), 2,2´,3,4´,5,5´,6 (CB-187), 2,3,3´,4,4´,5,5´-heptachlorobiphenyl (CB-189), 
2,2´,3,3´,4,4´,5,5´-octachlorobiphenyl (CB-194), 2,2´,3,3´,4,4´,5,6,6´-nonachlorobiphenyl 
(CB-207) and 2,2´,3,3´,4,4´,5,5´,6,6´-decachlorobiphenyl (CB-209) were purchased from 
AccuStandard Inc. (New Haven, CT). TriBP and tetrabromo-o-cresol (TBCr) were obtained 
from Aldrich (Milwaukee, WI) and PeBP from Acros (Geel, Belgium). 
Chlorotribromobisphenol-A (CtriBBP-A) was a gift from the Wallenberg Laboratory 
(University of Stockholm, Sweden).  
  
All solvents were of pesticide grade, and were purchased from LabScan (Dublin, Ireland). 
Sulphuric acid (H2SO4) and formic acid of analytical grade, Silica gel 60 (0.063-0.200 mm) 
for column chromatography and sodium sulphate (Na2SO4) for organic trace analysis was 
obtained from Merck (Darmstadt, Germany). N-methyl-N-nitroso-p-toluenesulfonamide 
(Diazald) was purchased from Aldrich (Milwaukee, WI). Water was purified using an Elga 
Option 4 Water Purifier device (Elga, Bucks, UK). 
 
All glassware was washed in 2.5% RBS 25 foaming cleaner (Chemical Products, Brussels, 
Belgium) rinsed with distilled water, and subsequently heated at 450°C for 4 h (volumetric 
equipment was not heated). 
 
2.1.1 SPE columns and equipment 
Oasis® HLB custom-made solid phase extraction cartridges (540 mg/ 3 mL) were purchased 
from Waters Corporation (Milford, MA). For preliminary method development, Isolute 101 
(200 mg/ 3 mL) obtained from International Sorbent Technology (Mid Glamorgan, UK) and 
Strata-X (60 mg/ 3 mL) from Phenomenex (Torrance, CA) was used. 
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2.2  Samples 
 
2.2.1 Validation samples 
For method validation horse serum from Sigma-Aldrich (H-1270) was used. The serum was 
homogenized by sonication in a Branson 2510E-MT ultrasonic cleaner for 5 minutes. The 
serum was then divided into ten sub-samples of 50 mL each, and stored at -18°C until 
analysis. As procedural blanks five mL of purified, sterilized water containing 0.9% sodium 
chloride was used. 
 
2.2.2 Sample pools from Norway 
A study was performed on two series of pooled serum samples from a local bio-bank at the 
National Institute of Public Health. The serum had been sampled from different county 
hospitals in Norway and stored at - 20°C. The first series (later referred to as the time-trend 
study) was restricted to men in the age group 40-50 years, to limit variation of body burden 
with gender and age. Five hundred µL of serum from each individual was pooled and stored 
at - 20°C. Serum samples from 2002 were chosen for study on BFRs and PCBs levels in 
groups with different age and gender (later referred to as the age-trend study). In the serum 
bank the individuals had been divided into eight age groups, serum from 20 individuals was 
pooled in each age group. For the 0-4 years old where limited sample volume was available, 
only 250 µL was taken from each individual, 29 individuals in total. In the 1997 pool, serum 
from 14 individuals was sampled because of limited sample volume available from this year. 
Details concerning the sample pools are listed in Table D1 in appendix. In addition five 
sample pools prepared earlier was incorporated in the study (1977, 1982, 1988, 1991 and 
1994). 
 
2.2.3 Control samples 
As control samples for the PCBs, three samples from an interlaboratory comparison study 
administrated by Institute national de santé publique du Québec, Arctic Monitoring and 
Assessment Programme (AMAP) was used. The samples were pooled human serum spiked 
with PCBs at different levels.  
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2.3  Preparation of standard solutions 
Stock solutions and dilutions from stock solutions were made volumetrically. Mixtures of 
analytes were made at eight levels for PBDEs and phenols in the concentration range of 0.1-
40 pg/µL for all PBDEs except BDE-209, which were in the concentration range of 1-400 
pg/µL. For the phenols the concentrations were in the range of 0.05-29 pg TriBP/µL, 0.1-58 
pg PeBP/µL and 0.2-116 pg TBBP-A/µL. Analyte mixtures of PCBs were made at twelve 
levels in the concentration range of 0.1-490 pg/µL (0.1-500 pg/µL for mono-ortho PCB). This 
mixture also contained the following 13C internal standards: HCB, CB-28, CB-52, CB-101, 
CB-123, CB-118, CB-114, CB-153, CB-105, CB-138, CB-167, CB-180, CB-156, CB-157, 
CB-170, CB-189, CB-194 and CB-209 with concentration 10 pg/µL for all except HCB 
which was 15 pg/µL. 
The internal standard solution for PBDE consisted of BDE-18, BDE-51, 13C-BDE-77, BDE-
103, BDE-156, BDE-181 and 13C-BDE-209 with concentration 2.5 pg/µL for all compounds 
except 13C-BDE-209 which were 25 pg/µL. Internal standards (ISTDs) for phenols consisted 
of 1 pg/µL TBCr and 3 pg/µL CtriBBP-A. Two separate solutions of ISTDs were made for 
PCBs, one for mono-ortho PCBs with concentration 5 pg/µL and the following 13C 
congeners; CB-105, CB-114, CB-118, CB-123, CB-156, CB-157, CB-167 and CB-189. The 
other PCB ISTD contained the following 13C congeners: HCB, CB-28, CB-52, CB-101, CB-
153, CB-138, CB-180, CB-170, CB-194 and CB-209 with concentration 20 pg/µL. As 
recovery standard, CB-207 was used with the concentration 8.75 pg/µL. 
 
The BFR standards (PBDEs and phenols) used for calibration were prepared by mixing 30 µL 
standard solution with 30 µL internal standard solution and 15 µL recovery standard. The 
PCB standards were prepared by mixing 30 µL standard solution (with ISTDs) with 15 µL 
recovery standard.  
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2.4  Instrumentation 
 
2.4.1 ASPEC 
The solid phase extraction was performed using an ASPEC XL4 from Gilson (Middleton, 
WI). ASPEC XL4 is a rapid and robust 4-channel system, each channel being equipped with 
its own syringe pump and needle. Four 2-way communal solvent ports permit the method to 
select from 8 solvent-bottles by switching the ports, in addition solvents placed in tubes on 
the sample tray can be used. 
 
 
2.4.2 GC-MS 
The chromatographic separation was performed on an HP (Avondale, PA) 6890 gas 
chromatograph equipped with an HP 7683 automatic liquid sampler. The HP ChemStation 
B.02.05 and D.01.02 software’s operated the system. Columns used for separation of the 
individual components are shown in Table 1. 
 
Table 1. Columns used in analysis POPs. 
Compounds Columna Length (m) Internal diameter (mm)  Film thickness (µm) 
Phenols DB-5MS 25 0.25 0.25 
PBDEs DB-5MS 25 0.25 0.25 
BDE-209 DB-5MS 15 0.25 0.10 
PCBs DB-5MS 60 0.25 0.25 
a 5% Phenyl 95% dimethyl polysilxane, Agilent Technologies, Inc., CA. 
 
A deactivated retention gap of 1.5 m × 0.32 mm I.D. fused silica (Agilent Technologies, Inc., 
CA) was used in front of all the columns. Samples of 2 µL were injected at 290°C in pulsed 
splittless mode with a pulsed pressure of 3.79 bar for 1.5 minutes. Helium (99.998%, Aga) 
was used as a carrier gas, and the flow was held constant at 1.2 mL/min. 
Temperature programs used for the different compounds are listed in Table 2-4. 
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Table 2. Temperature program for the PCBs. 
Step °C/min Next °C Hold min Runtime 
Initial  100 1.0 1.0 
Ramp 1 30 190 1.0 5.0 
Ramp 2 2.0 250 0.0 35.0 
Ramp 3 5.0 300 0.0 45.0 
Ramp 4 20 325 1.0 47.25 
 
Table 3. Temperature program for the phenols and PBDEs. 
Step °C/min Next °C Hold min Runtime 
Initial  90 1.0 1.0 
Ramp 1 20 190 0.0 6.0 
Ramp 2 5.0 230 0.0 14.00 
Ramp 3 1.0 235 0.0 19.00 
Ramp 4 3.5 250 0.0 23.29 
Ramp 5 30 325 4.0 29.79 
 
Table 4. Temperature program for BDE-209. 
Step °C/min Next °C Hold min Runtime 
Initial  90 1.0 1.0 
Ramp 1 20 190 0.0 6.0 
Ramp 2 4.0 230 0.0 16.00 
Ramp 3 1.0 235 0.0 21.00 
Ramp 4 3.5 250 0.0 25.29 
Ramp 5 30 325 4.0 31.79 
 
The mass spectrometer, an HP 5973 MSD was operated in electron capture negative 
ionization mode (ECNI) for the determination of PBDEs, phenols and PCBs, in addition some 
of the PCBs were determined in electron ionization mode (EI). Methane (99.99%, Aga) was 
used as buffer gas in the ECNI mode. The parameters applied for the ion source, quadrupole, 
MS interface and the electron energy are listed in Table 5. 
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Table 5. MS parameters. 
Compounds Ion source 
(°C) 
Quadrupole (°C) MS interface (°C) Electron energy (eV) 
PBDEs/Phenols 250 106 300 123.7 
BDE-209 200 106 300 119.1 
PCBs (CI mode) 150 106 300 128.4 
PCBs (EI mode) 230 150 300 69.9 
 
 
2.4.3 Qualitative identification of BFRs and PCBs 
The analytes were identified by comparing their retention time with the respective retention 
time of the calibration standards. The brominated compounds were monitored at m/z 79 and 
81, BDE-209 was monitored at m/z 484.6 and 486.6. Both ions were used for identification 
and the abundance ratio was used for confirmation. The PCBs were monitored at the 
respective masses for their molecular ions: m/z 256 (tri-CB), m/z 292 (tetra-CB), m/z 326 
(penta-CB), m/z 360 (hexa-CB), m/z 394 (hepta-CB), m/z 430 (octa-CB), m/z 464 (nona-CB) 
and m/z 498 for (deca-CB). The PCBs without 13C-ISTD were monitored at m/z 35 and m/z 37 
in addition to their molecular ions.  
 
2.5  Quantification 
All compounds were quantified using peak areas obtained by integration in the HP 
chemstation software and Internal standard calibration. 
 
2.6  Determination of lipid content 
The lipid content of the pooled serum samples was determined at The National Hospital of 
Norway (Oslo, Norway) according to a method described by Grimvall et al. [52]. Details 
concerning fat content and number of individuals represented in each pool are summarized in 
Table D1 in appendix. 
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2.7  Sample preparation 
 
2.7.1 Homogenization and dilution 
The frozen serum samples were thawed in a refrigerator at 4°C overnight and brought to 
ambient temperature. The samples were then sonicated as described in section 2.2.1 for 5 
minutes to ensure that representative sub samples were obtained. 
 
Approximately 5 g of each serum sample were weighed into separate tubes (15 mL with 
screw cap) and spiked, see appendix section B. The samples were then whirlmixed, sonicated 
for 5 minutes and placed in a refrigerator overnight to equilibrate. After bringing the samples 
to ambient temperature and whirlmixing for 5 minutes, 5 mL of formic acid/2-propanol (4+1 
v/v) were added to denaturate the proteins. The samples were again sonicated for 5 minutes 
and stored in a dark place for 50 minutes. Finally 5 mL of 20% 2-propanol was added to each 
tube to dilute the sample, followed by another 5 minutes of sonication. (The samples were 
now ready for extraction). 
 
2.7.2 Solid Phase extraction 
 
2.7.2.1 Extraction procedure 
The extraction procedure was performed on an ASPEC XL4, see section 2.4.1, and is outlined 
in Table 6. To eliminate impurities in the column material, the columns were prewashed with 
methanol and methanol/dichloromethane. The columns were then conditioned with methanol 
and methanol/water before the diluted sample was applied. The sample tubes were washed 
with methanol/water, to remove residual serum, which was then added to the columns. The 
columns were then washed with 2-propanol and dried for 45 minutes with nitrogen (99.999%, 
Aga), this was done to remove residual water in the columns and thereby making the pores in 
the packing material fully accessible to the eluent and also prohibiting water in the eluate. 
Three times during the drying process 20 µL of 70% methanol were added to facilitate 
extrusion of water from the micropores of the sorbent material.  After drying the analytes 
were eluted with methanol/dichloromethane. 
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Table 6. SPE procedure. 
Step Process Application Flow 
1 Prewash 3 mL methanol 1.5 mL/min 
2 Prewash 3 mL 30% methanol in dichloromethane 1.5 mL/min 
3 Condition 5 mL methanol 1.5 mL/min 
4 Condition 5 mL 5% methanol in water 1.5 mL/min 
5 Load 15 mL diluted plasma or serum sample 0.4 mL/min 
6 Load 5 mL 5% methanol in water 0.4 mL/min 
7 Wash 10 mL 5% 2-propanol 1.5 mL/min 
8 Dry 1.0 bar N2 for 45 min.  
9 Elute 12 mL 30% methanol in dichloromethane 0.4 mL/min 
 
2.7.2.2 Optimization of the extraction procedure  
During method development several SPE columns were evaluated for extraction of POPs 
from serum. Different solvents and solvent mixtures were investigated in order to find the 
optimal eluent. Approximately 5 g of horse serum was spiked with 30 µL of standard solution 
at an intermediate concentration level, and prepared according to section 2.7.2.2. Lipids were 
then removed from the sample as described in section 2.7.3, concentration and derivatization 
was performed according to section 2.7.4. 
 
2.7.3 Additional clean-up (lipid removal) 
Prior to the additional clean-up step, the eluates from the SPE columns were evaporated to a 
few µL at 40°C in a TurboVap LV (Zymark, Hopkinton, MA) under a gentle stream of 
nitrogen (99.999%, Aga). The residues were redissolved in 3.5 mL n-
heptane/dichloromethane (3:1, v/v), and the extracts were subsequently subjected to the 
clean-up procedure. 
 
2.7.3.1 Preparation of sulphuric-acid silica columns 
Silica gel 60 rinsed with methanol and dichloromethane was activated overnight at 130°C. 
Sodium sulphate was dried at 600°C overnight. 
 
The columns were packed using empty SPE tubes of polyethylene from Sigma-Aldrich 
(St.Louis, MO). The activated silica was mixed with concentrated sulphuric acid in the ratio 
3:1 (w/v), and shaken until a homogenous mixture was obtained. Sulphuric-acid silica and 
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sodium sulphate were then filled into the empty SPE tubes, creating alternating layers, (Figure 
4). Using columns with alternating layers was found to be more efficient than a one-layer 
column. The sodium sulphate was added for removal of excess water in the sample extracts. 
 
 
Figure 4. Packed sulphuric-acid silica column. 
 
The additional clean-up step was also performed on the ASPEC XL4 from Gilson. 
 
2.7.3.2  Clean-up procedure 
The clean-up procedure is outlined in Table 7. First the columns were washed with heptane to 
remove air bubbles, and then conditioned with n-heptane/dichloromethane. The redissolved 
extracts were then applied and the eluate immediately collected in a glass tube. The initial 
tube was washed with n-heptane/dichloromethane, and then applied to the column. Columns 
were eluted with another portion of n-heptane/dichloromethane and dried by pushing air 
through. 
 
Table 7. Clean-up procedure. 
Step Process Application Flow 
1 Wash 10 mL n-heptane 1.0 mL/min 
2 Condition 3.0 mL n-heptan/dichloromethane (3:1, v/v) 1.0 mL/min 
3 Load and collect 3.7 mL sample 0.4 mL/min 
4 Load and collect 2.2 mL n-heptan/dichloromethane (3:1, v/v) 0.4 mL/min 
5 Elute 4.0 mL n-heptan/dichloromethane (3:1, v/v) 0.4 mL/min 
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2.7.3.3 Optimization of the clean-up procedure 
Since the clean-up method is being used for both milk and serum samples it was important to 
find the optimal conditions were the largest amounts of lipids could be removed, with the 
limitation being the use of 3 mL SPE tubes. Different bed volumes of sorbent, and strength of 
the sulphuric acid silica were investigated. The effect of dividing the columns into several 
layers was also examined. Different amounts of soy oil were dissolved in n-
heptane/dichloromethane (3:1, v/v), and then applied to the columns as described in section 
2.7.3.2. The eluates were collected in pre-weighed and heated (110°C) beakers and 
evaporated under a stream of nitrogen. After the evaporation the beakers were weighed and 
the amount of lipids remaining calculated. 
 
The possible loss of POPs during clean-up was examined by spiking 3.5 mL of n-
heptane/dichloromethane (3:1, v/v) with 30 µL of a standard solution and applying it to the 
columns as described in section 2.7.3.2. 
 
 
2.7.4 Derivatization 
The phenolic compounds were methylated by derivatization of the hydroxy groups. 
Diazomethane, synthesized by base-catalyzed decomposition of N-methyl-N-nitroso-p-
toluensulfonamid (diazald) [53], was used as alkylating reagent. 
 
The sample extracts from the additional clean-up step were concentrated under a gentle 
stream of nitrogen to a final volume of approximately 30 µL. The extracts were derivatized by 
adding 25 µL of diazomethane, the samples were then whirlmixed and left in a dark place at 
ambient temperature for 30 minutes. The excess of derivatization reagent was evaporated by 
heating at 40°C for approximately 15 minutes (or until the yellow colour disappeared). 
Finally 15 µL of recovery standard (CB-207) was added, the samples were now ready for GC-
MS analysis. 
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2.8  Method validation 
The presented method was validated according to guidelines from Tønseth and Døhl [54] and 
the International Conference of Harmonisation [55]. Seventeen samples were spiked at five 
levels in the range of 1.2-120 pg PBDEs/g serum, 12-1200 pg BDE-209/g serum, 1.2-120 pg 
PeBP/g serum, 2.4-240 pg TBBP-A/g serum and 3-300 pg PCBs/g serum, see Table 9. A 
solvent exchange was performed on the spiking solutions prior to the sample preparation, to 
limit the volume of organic solvents (section A, appendix).  
Each level was prepared in four replicates except level four which consisted of one replicate. 
Four horse serum samples were extracted, and three of them were added ISTDs. The fourth 
non-spiked sample was used to verify that the horse serum did not contain any native 
concentrations of the ISTDs. In addition three procedural blanks were extracted. The samples 
were extracted in random order, in three batches over a period of two weeks. 
 
The intermediate precision was investigated after two months by spiking four horse serum 
samples at an intermediate concentration level. 
 
The sample extracts were injected once per analysis. Calibration standards were injected three 
times per sequence, at the beginning, middle and at the end. Calibration curves were made 
from the calibration standards injected at the beginning and at the end of the sequence. 
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3.  Results and discussion 
 
3.1  Automation 
When automating the method and transferring it to the ASPEC XL4 there were some 
challenges. In the manual SPE method, lipid decomposition was performed directly on the 
columns with concentrated sulphuric acid, this was not possible on the ASPEC, since tubing 
and needles were not compatible with sulphuric acid. Some other limitations were the SPE 
columns that were limited to one and three mL cartridges and the collection tubes, which 
were limited to 6 mL. When eluting with more than 6 mL several collection tubes must be 
used, leading to a limitation in the number of samples that can be extracted.  
 
The ASPEC is designed to minimize carry-over. The only liquids that ever come into contact 
with the syringe pumps are those from the reservoir. The liquids transferred from the sample 
tray come into contact with the needle and transfer tubing only. Carry-over was investigated 
by spiking four horse serum samples, these samples were extracted followed by the extraction 
of four blanks (sterilized water containing 0.9% sodium chloride). The blanks were then 
analyzed for phenols and PBDEs. The most abundant congeners found in the blanks were 
BDE-47, BDE-99 and TriBP, these compounds have previously been reported in procedural 
blanks [29]. The level of these compounds found in this experiment was comparable with 
levels found in other procedural blanks.  A carry-over effect was therefore not found. 
 
Some of the advantages of using an ASPEC are the small consumption of solvents compared 
to normal LLE and the small need of personnel. Up to 24 samples can be extracted with the 
SPE method outlined in section 2.7.2.1 within 24 hours. The additional clean-up method 
outlined in section 2.7.3.2 is less time consuming and 96 samples can be cleaned-up within 
the same time period.   
 
3.2      Optimization of SPE 
Isolute 101 was the first column to be investigated. Isolute 101 is a highly cross-liked PS-
DVB copolymer, with spherical particles of 60 µm, pore size of 100 Å and a surface area of 
approximately 500 m2/g, (Figure 5). It was found that spiking directly on the columns or in 
blanks gave a higher yield than spiking in serum, indicating that the spiked compounds were 
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not fully released from the matrix. The most lipophilic PBDEs were also found to give a poor 
recovery compared to the less lipophilic PBDEs. 
The recovery of POPs in horse serum was improved by performing the sample preparation 
(weighing, denaturation and dilution) in sample tubes, (instead of Duran flasks), which could 
be used directly on the ASPEC. By doing this an additional transfer step was eliminated. With 
the main problem being the poor recovery of the most lipophilic PBDEs, it was investigated if 
these compounds were lost during sample application or washing of the columns. The 
strength of the dilution solvent and washing solution was reduced to see if this would prevent 
a possible breakthrough of the compounds. A 7% 2-propanol solution was used for dilution 
(previously 20%) and a 5% methanol solution was used for washing (previously 10%). The 
analytes was eluted with 100% dichloromethane. No improvement was seen for the lipophilic 
PBDEs, and an overall recovery of about 60% was found. 
 
 
Figure 5. Polystyrene-divinylbenzene copolymer sorbent, from Isolute 101 columns. 
 
Elution solvents and elution volumes was also investigated. The recovery of PBDEs and 
phenols when eluting with different solvents was examined. The overall mean recovery of 
PBDEs when eluting with the different solvents was: 77.6% when eluting with 12 mL of 
100% dichloromethane, 46.4% when eluting in two steps, first with 6 mL of dichloromethane 
and then with 6 mL dichloromethane in heptane (1:1, v/v) and 75.7% recovery was found 
when eluting with 12 mL of toluene (Figure 6). For the phenols the best yields in this 
experiment was found when eluting with 6 mL dichloromethane and 6 mL dichloromethane in 
heptane (1:1, v/v), (134.3% TriBP, 96.2% PeBP and 93.5% TBBP-A).  
 
Dichloromethane was found to be a good elution solvent for the PBDEs and PCBs, but to 
improve the results for the phenols methanol was added to the solution. The methanol will 
facilitate the elution by interrupting hydrophobic interaction and increasing the solubility of 
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phenols in the elution solvent. A better yield was not obtained by increasing the elution 
volume above 12 mL. 
 
Recovery of PBDEs on isolute 101 columns
0,00
20,00
40,00
60,00
80,00
100,00
120,00
BDE-28 BDE-37 BDE-47 BDE-100 BDE-119 BDE-99 BDE-85 BDE-154 BDE-153 BDE-138 BDE-183
Compounds
M
ea
n 
pe
rc
en
t r
ec
ov
er
y 
(n
=2
)
DCM
Toluen
DCM+DCM in heptane
Figure 6. Recovery of PBDEs with different elution solvents performed on isolute 101 columns. 
 
 
The spiking components were dissolved in organic solvents, which might lead to a 
breakthrough of analytes on the SPE columns during application. The effect of a solvent 
exchange from these organic solvents to more polar solvents was investigated and ethanol 
was found suitable (Appendix section A).  
Strata-X and Oasis HLB columns were also examined. Strata-X is a patent pending polymeric 
sorbent with similar features as Oasis HLB. The Strata-X columns had a particle size of 33 
µm, 85 Å pore size and a surface area of 800 m2/g. Oasis HLB is a hydrophilic-lipophilic 
water-wettable reversed phase sorbent. It is made from two monomers, the hydrophilic N-
vinylpyrrolidone (Figure 7) and the lipophilic divinylbenzene (Figure 5). The N-
vinylpyrrolidone, provides an enhanced retention of polar analytes (phenols). The Oasis HLB 
columns have a surface area of 810 m2/g, pore size 80 Å and an average particle diameter of 
60 µm. 
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Figure 7. N-Vinylpyrrolidone monomer. 
 
Oasis HLB were purchased from Waters as bulk, and empty 3 mL cartridges were packed 
with 250, 300 and 500 mg of sorbent and compared with 3 mL Strata-X columns with 500 mg 
sorbent. The results are shown in Figure 8. 
Samples were prepared as described in section 2.7, and a solvent exchange was performed see 
appendix section A. 
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Figure 8. Mean percent recovery of PBDEs spiked in horse serum  (n=4) obtained on Oasis HLB 
columns with different sorbent amounts, and Strata-x columns.  
 
Figure 8 demonstrates the effect of different sorbent amounts. As can be seen, the recovery 
increases with increasing sorbent amounts for the PBDEs, the same trend was also seen with 
PCBs and phenols. High recoveries are obtained for BDE-47 and BDE-99 because of native 
concentrations in the horse serum or contribution from laboratory air. The highest overall 
recovery were obtained with the Strata-X columns, but the small particle size (33µm 
compared to Oasis HLB 60µm) caused pressure problems, especially with more viscous 
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samples such as plasma and these columns were therefore not found suitable for this 
application. The Oasis columns were then chosen, and the sorbent amount maximized. 
Custom-packed columns with 540 mg sorbent in 3 mL cartridges were purchased from 
waters. These columns were used in the method validation and in the following application. 
 
3.3 Optimization of clean-up 
In human serum there is about 0.5% lipids, but breast milk consists of approximately 3-5% 
lipids [56]. A column had to be designed for the removal of at least 3% lipids in 5 g samples 
of serum or milk (0.15 g lipids). Previously, columns filled with 1 g of sulphuric acid-silica 
(1:3 v/w) and 1.5 g of sodium sulphate had been used. Investigation of these columns 
revealed that they were only able to remove about 1.5% lipids. The bed volume was then 
maximized using 1.6 g of sulphuric acid-silica (1:3 v/w) and 1 g of sodium sulphate, the 
columns were now able to remove about 3% lipids. The effect of dividing the column into 
layers was then investigated. By creating a double-layer column as seen in Figure 4, up to 4% 
lipids were removed. The use of a more acidic sulphuric acid-silica (1:2 v/w) was also 
investigated, but was not found to be more efficient. Dividing the column into more than two 
layers did not improve the columns efficiency. It was found that an additional 0.1 g layer of 
activated silica on top of the columns provided cleaner extracts, due to the removal of 
cholesterol [57], this was applied to the columns used for clean-up of milk samples. The loss 
of PBDEs on the sulphuric acid-silica columns was investigated and the overall recovery was 
about 96%, so there was no considerable loss at this step. 
 
The use of aminopropyl columns for the removal of lipids was also considered. The load limit 
on 500 mg aminopropyl columns was found to be approximately 10 mg of total lipid [58], and 
therefore these columns were not chosen. 
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3.4 Validation 
 
3.4.1 Evaluation of internal standards 
All PCBs were quantified using 13C-ISTDs. For the PBDEs this was not an option when 
operating the gas chromatograph in NCI mode, so several BDE-congeners were investigated 
as potential ISTDs. Some of the criteria used when choosing the ISTDs were chemical 
structure and retention time. BDE-18 (tri-BDE) was found to the most suitable ISTD for 
BDE-28 (tri-BDE) and BDE-37 (tri-BDE). For BDE-47, which is a tetra-BDE, both BDE-51 
(tetra-BDE) and BDE-77 (tetra-BDE) were examined as ISTDs. Good results were found with 
both BDE-51 and BDE-77, but BDE-51 was chosen because of the closeness in retention 
times. The tetra-BDE-77 and penta-BDE-103 were evaluated as ISTDs for BDE-99 and BDE-
100, which both are penta-BDEs. BDE-103 were found to be the most suitable, being a penta-
BDE and closest in retention time. For BDE-85 and BDE-119 which both are penta-BDEs, 
BDE-103 (penta-BDE) was found to be the most suitable ISTD. For the hexa-BDEs, BDE-
153 and BDE-154, three ISTDs were evaluated, BDE-77 (tetra-BDE), BDE-103 (penta-BDE) 
and BDE-156 (hexa-BDE). All three BDEs were found suitable, with BDE-156 being closest 
in retention time and chemical structure, but less reproducible results were obtained with this 
compound compared to BDE-77 and BDE-103. The “second best” ISTD was therefore 
chosen, that being BDE-103 which was closer in retention time than BDE-77. BDE-183 is a 
hepta-BDE, and BDE-77 and BDE-181 (hepta-BDE) were evaluated as ISTDs for this 
congener. BDE-181 was found to be the most suitable ISTD.  
BDE-77 and brominated biphenyl-77 (BB-77) has previously been used as ISTDs for all 
PBDEs [19], and BDE-77 was therefore used for comparison when evaluating new ISTDs. 
All the ISTDs used in analysis of PCBs, PBDEs and phenols are listed in appendix section C. 
 
3.4.2 Linearity 
 
3.4.2.1 Calibration linearity 
The linearity of the calibration curves was examined by the correlation coefficient, r. The area 
ratio between the analyte and ISTD was plotted against the corresponding concentration ratio. 
The standards were injected three times during an analysis sequence. The first and last 
injection was used in the calibration curve. Eight levels were used in the calibration curves for 
PBDEs and phenols, for the PCBs ten levels were used, the ranges are listed in section 2.3. 
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Because of the wide concentration range, two calibration curves were designed for each 
compound group, one in the low concentration range and the other in the high concentration 
range, each with six levels. Linear fit was used in all calibration curves except for the 
pesticide HCB and the phenols in the high concentration range, where a quadratic fit was 
used. All correlation values were in the range 0.989-1.000, with the lowest value accounting 
for the phenol PeBP.  
 
3.4.2.2 Method linearity 
The method linearity was examined by plotting the concentration of POPs found in the spiked 
samples against the concentration added. The native concentration of POPs in the horse 
serum was calculated, and this value was subtracted from the concentrations found in the 
spiked samples. Both the results from the initial validation and the second round when 
investigating the intermediate precision (section 2.8) were incorporated when evaluating the 
linearity. Regression results are presented in Table 8. 
Because of high native concentrations of some of the PCBs (section 3.4.8) in the horse serum, 
the levels I, II and in some cases also level III could not be accurately quantified, and these 
compounds are therefore not listed in Table 8. 
 
Table 8. Regression data obtained from the spiked validation samples (n=21). 
Compounds Slope (a) Intercept (b) Correlation coefficient (r) 
BDE-28 0.8303 4.7361 0.9993 
BDE-37 0.7657 5.0026 0.9996 
BDE-47 0.6192 9.4487 0.9968 
BDE-85 0.9190 2.7468 0.9999 
BDE-99 0.8101 4.1520 0.9999 
BDE-100 0.7857 4.6235 0.9998 
BDE-119 0.8141 4.2840 0.9994 
BDE-138 0.8554 3.5654 0.9997 
BDE-153 0.9207 0.3592 0.9999 
BDE-154 0.9005 1.3140 1.0000 
BDE-183 0.9904 -2.3724 0.9998 
BDE-209 0.9171 79.6490 0.9995 
PeBP 1.1295 -4.6157 0.9994 
TBBP-A 1.1749 -4.2801 0.9998 
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Table 8. Continued    
Compounds Slope (a) Intercept (b) Correlation coefficient (r) 
HCB 0.9528 -0.5882 0.9999 
OCS 0.9844 -1.5305 1.0000 
CB-66 1.1043 -28.5480 0.9981 
CB-81 1.0195 10.5710 0.9995 
CB-105 1.0202 -0.7571 1.0000 
CB-114 0.9897 2.1158 0.9999 
CB-123 1.0042 -3.4690 0.9996 
CB-128 0.9542 -1.8163 1.0000 
CB-156 0.9934 3.4345 1.0000 
CB-157 0.9932 0.7285 1.0000 
CB-167 0.9929 2.5612 1.0000 
CB-170 1.0416 -1.6148 1.0000 
CB-180 1.0212 -3.4718 0.9999 
CB-183 0.8828 8.4833 0.9999 
CB-187 0.8771 8.3379 0.9999 
CB-189 1.0146 0.4028 0.9999 
CB-194 1.0195 -1.6568 1.0000 
CB-209 1.0110 -1.2677 1.0000 
 
3.4.3 Accuracy and precision 
The accuracy was determined as recovery relative to ISTDs. The accuracy and precision at 
the five spiking levels (Table 9) outlined in section 2.8 were calculated and the results are 
presented in Table 10. Corrections were made for the native concentrations in the horse 
serum. 
 
Table 9. Concentrations in pg/g serum of POPs in the spiked validation samples.  
Level TriBP PeBP TBBP-A PBDE BDE-209 PCB m-o PCB, HCB, OCS 
I 0.6 1.2 2.4 1.2 12 3.36 3.0 
II 1.2 2.4 4.8 2.4 24 6.72 6.0 
III 3.0 6.0 12 6.0 60 15.12 15 
IV 9.0 18 36 18 180 60.48 60 
V 60 120 240 120 1200 302.4 300 
The number of replicates at all levels was 4, except at level IV were only one replicate was used. 
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Table 10. Mean accuracies of the different POPs found in spiked horse serum from the validation 
study. 
Compounds Level n Accuracy 
(%) 
RSD (%) Compounds Level n Accuracy 
(%) 
RSD 
(%) 
BDE-28 I 4 87 8.1 BDE-37 I 4 97 11 
 II 4 102 8.0  II 4 98 1.5 
 III 4 97 3.2  III 4 96 3.6 
 IV 1 99   IV 1 90  
 V 4 82 8.8  V 4 83 8.1 
BDE-47 I 4 64 4.4 BDE-85 I 4 101 3.0 
 II 4 94 17  II 4 102 4.4 
 III 4 99 6.5  III 4 100 1.4 
 IV 1 89   IV 1 99  
 V 4 71 7.9  V 4 92 2.7 
BDE-99 I 4 109 25 BDE-100 I 4 100 3.4 
 II 4 112 4.5  II 4 101 3.3 
 III 4 96 4.5  III 4 97 3.4 
 IV 1 90   IV 1 88  
 V 4 84 2.2  V 4 81 1.5 
BDE-119 I 4 95 3.4 BDE-138 I 4 85 8.8 
 II 4 91 3.5  II 4 97 2.5 
 III 4 94 3.5  III 4 93 6.2 
 IV 1 95   IV 1 97  
 V 4 94 3.3  V 4 87 1.2 
BDE-153 I 4 96 4.4 BDE-154 I 4 93 2.7 
 II 4 99 2.8  II 4 97 4.6 
 III 4 98 2.2  III 4 99 5.2 
 IV 1 94   IV 1 95  
 V 4 96 3.0  V 4 90 0.6 
BDE-183 I 4 101 2.0 BDE-209 I 4 108 56 
 II 4 104 8.0  II 4 150 33 
 III 4 98 7.4  III 4 103 13 
 IV 1 90   IV 1 100  
 V 4 90 6.7  V 4 95 1.3 
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Table 10.  Continued 
Compounds Level n Accuracy 
(%) 
RSD (%) Compounds Level n Accuracy 
(%) 
RSD 
(%) 
HCBb I 4 78 15 OCS I 4 89 6.2 
 II 4 62 14  II 4 100 10 
 III 4 104 5.3  III 4 101 4.0 
 IV 1 97   IV 1 98  
 V 4 97 1.9  V 4 102 3.2 
CB-18b I 4 n.aa  CB-28b I 4 n.a  
 II 4 n.a   II 4 n.a  
 III 4 n.a   III 4 127 27 
 IV 1 65   IV 1 97  
 V 4 88 11  V 4 97 3.7 
CB-52b I 4 n.a  CB-66b I 4 105 15 
 II 4 n.a   II 4 76 20 
 III 4 107 77  III 4 84 14 
 IV 1 98   IV 1 101  
  V 4 88 8.6  V 4 106 4.3 
CB-74 I 4 n.a  CB-81 I 4 88 11 
 II 4 n.a   II 4 103 10 
 III 4 94 5.1  III 4 112 7.3 
 IV 1 100   IV 1 113  
 V 4 100 3.6  V 4 105 1.7 
CB-99 I 4 n.a  CB-101 I 4 n.a  
 II 4 n.a   II 4 n.a  
 III 4 97 11  III 4 90 34 
 IV 1 106   IV 1 114  
 V 4 102 1.9  V 4 102 1.9 
CB-105 I 4 121 25 CB-110 I 4 n.a  
 II 4 111 20  II 4 n.a  
 III 4 107 1.5  III 4 n.a  
 IV 1 103   IV 1 98  
 V 4 102 2.3  V 4 112 4.5 
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Table 10. Continued 
Compound Level n Accuracy 
(%) 
RSD (%) Compound Level n Accuracy 
(%) 
RSD 
(%) 
CB-114 I 4 99 2.6 CB-118 I 4 n.a  
 II 4 102 4.3  II 4 122 38 
 III 4 102 1.6  III 4 100 14 
 IV 1 102   IV 1 102  
 V 4 101 1.1  V 4 102 0.3 
CB-123 I 4 29 22 CB-128 I 4 97 16 
 II 4 69 12  II 4 94 10 
 III 4 87 3.0  III 4 94 3.3 
 IV 1 106   IV 1 96  
 V 4 102 1.4  V 4 97 1.7 
CB-138 I 4 n.a  CB-153 I 4 n.a  
 II 4 n.a   II 4 n.a  
 III 4 96 11  III 4 107 15 
 IV 1 94   IV 1 104  
 V 4 96 1.4  V 4 103 0.6 
CB-156 I 4 108 6.1 CB-157 I 4 78 3.5 
 II 4 109 1.8  II 4 83 10 
 III 4 105 1.6  III 4 98 1.1 
 IV 1 102   IV 1 102  
 V 4 101 0.7  V 4 101 1.1 
CB-167 I 4 104 5.6 CB-170 I 4 102 14 
 II 4 106 4.2  II 4 105 5.0 
 III 4 101 2.2  III 4 105 2.6 
 IV 1 101   IV 1 103  
 V 4 100 0.3  V 4 104 0.6 
CB-180 I 4 104 39 CB-183 I 4 106 16 
 II 4 98 29  II 4 109 7.1 
 III 4 103 4.4  III 4 105 1.5 
 IV 1 102   IV 1 93  
 V 4 102 0.8  V 4 91 2.3 
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Table 10. Continued 
Compounds Level n Accuracy 
(%) 
RSD (%) Compounds Level n Accuracy 
(%) 
RSD 
(%) 
CB-187 I 4 107 37 CB-189 I 4 79 3.8 
 II 4 109 19  II 4 96 3.5 
 III 4 106 7.5  III 4 100 0.4 
 IV 1 92   IV 1 104  
 V 4 90 2.6  V 4 102 0.5 
CB-194 I 4 87 1.9 CB-209 I 4 90 3.8 
 II 4 97 2.4  II 4 97 2.5 
 III 4 101 1.4  III 4 100 1.4 
 IV 1 102   IV 1 101  
 V 4 102 0.5  V 4 102 0.7 
PeBP I 4 101 24 TBBP-A I 4 99 15 
 II 4 119 14  II 4 77 24 
 III 4 108 7.7  III 4 123 21 
 IV 1 99   IV 1 132  
 V 4 104 5.9  V 4 123 4.5 
naa because of high native concentrations of the compounds in the horse serum and procedural blanks 
these levels could not be accurately quantified. 
b These compounds were determined in EI mode, the other PCBs and OCS were determined in CI 
mode. 
 
 
The accuracy of the PBDEs were in the range of 64-150% with the mean being 95%, the RSD 
were in the range of 0.6-56% with a mean RSD of 6.9%. The high RSD-values found at low 
levels can be explained by the native concentrations of PBDEs found in the horse serum. The 
main PBDE congeners found in the horse serum was BDE-47, BDE-99 and BDE-209 
(section 3.4.8), and these congeners were the most difficult at low levels. The mean accuracy 
of the PCBs were in the range of 29-127%, with a mean accuracy of 99%, the RSD were in 
the range of 0.3-77% with mean RSD of 8.7%. Some of the PCBs were found in relatively 
high concentrations in the horse serum (section 3.4.8), causing trouble in the low 
concentration range. The accuracy of the organochlorine compounds HCB and OCS were in 
the range of 62-104% with the mean being 93%. The RSD were in the range of 1.9-15%, with 
mean RSD of 7.5%. The phenols accuracy was in the range of 77-132% with a mean 
accuracy of 109%, the RSD ranged from 4.5-24% and the mean was 15%. TriBP were also 
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investigated in the validation, but high levels of this compound in the horse serum and 
procedural blanks made the quantification difficult.  
 
3.4.4 Recovery of internal standards 
The recovery of the ISTDs was calculated against a GC-MS recovery standard (CB-207) 
added to the samples just before analysis. The recovery standard corrects for differences in 
the final sample extract volume, and variations in the injection volume. Equation 1 was used 
in calculations. 
 
(1) 
stdr
ISTD
rISTDr
ISTDrISTD
A
AsAsCstdC
sAsCstdC
⎟⎟⎠
⎞
⎜⎜⎝
⎛=
*)(*)(*)(
)(*)(*)(*100Recovery%  
Abbreviations: C: concentration, ISTD: Internal standard, std: standard solution, s: sample extract, A: 
area, r: recovery standard. 
 
Recovery was calculated in all the validation samples (n=17). Recovery of the ISTDs used for 
PBDEs were in the range of 64-89% with an overall recovery of 79%. The RSD was in the 
range 5-15% with an overall RSD of 9%.  TBCr and CtriBBP-A used as ISTD for the phenols 
had recoveries of 64% and 53% respectively, with RSD of 8% (TBCr) and 35% (CtriBBP-A). 
Recoveries of the PBDEs and phenols ISTDs are illustrated in Figure 9. The PCBs ISTDs had 
recoveries in the range 37-82%, with an overall recovery of 63%. The RSDs ranged from 5-
23% with an overall RSD of 9%, Figure 10 illustrates the results. 
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Figure 9. Recovery of internal standards used in the quantification of PBDEs and phenols. The 
relative standard deviation is shown as error bars (n=17). 
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Figure 10. Recovery of internal standards used in the quantification of PCBs. The relative standard 
deviation is shown as error bars (n=17). 
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From Figure 10 it can be seen that the most volatile PCBs and the pesticide HCB have 
somewhat lower recoveries than the other congeners. This might be due to the solvent 
exchange performed on the spiking solutions. Because of this effect the solvent exchange will 
not be performed in future sample preparations and is not performed in the following 
application. 
 
3.4.5 Intermediate precision 
Two months after the initial validation, four new horse serum samples were spiked at level III 
(Table 9) extracted and analyzed as described in section 2.7. The PCBs were only analyzed in 
CI mode. The accuracy and repeatability was calculated and the results were compared with 
the initial validation. Corrections were made for the native concentration of POPs in the horse 
serum. Calibration curves used for quantification are described in section 2.3. 
The mean accuracy found for the PBDEs at level III was 106% and the RSD was 4%. For the 
PCBs the accuracy was 98% and the RSD was 9%, CB-101 and CB-110 not included (due to 
high blank values). PeBP and TBBP-A had accuracies of 182% and 149% respectively, with 
RSD of 32.6% (PeBP) and 17.4% (TBBP-A). The organochlorine compound OCS had a 
mean accuracy of 93.1% and RSD of 4%. The difference in accuracy (relative to the initial 
validation), for the PBDEs were in the range of –1 to 18% with a mean difference of ± 9%, 
for the PCBs the difference was in the range of –32 to 22% with a mean difference of ± 8%.  
PeBP and TBBP-A had a difference of +74% and +26% respectively compared to the initial 
validation. OCS had a difference of ± 8%. 
 
3.4.6 Selectivity and retention stability 
Throughout the chromatographic analysis of the validation samples, the compounds retention 
time was highly stable and within ± 0.1 minutes. All compounds were baseline separated 
except CB-138, which were eluted between two other compounds (CB-163 and CB-164). 
Little interference was observed from matrix components. A chromatogram of a spiked horse 
serum sample at level III, for the PBDEs, is shown in Figure 11. 
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Figure 11. Chromatogram of level III (PBDEs) spiked in a horse serum sample. The numbers and 
letters corresponds to the following compounds: 1) BDE-28, 2) BDE-37, 3) BDE-47, 4) BDE-100, 5) 
BDE-119, 6) BDE-99, 7) BDE-85, 8) BDE-154, 9) BDE-153, 10) BDE-138, 11) BDE-183. A) BDE-
18, B) BDE-51, C) C13BDE-77, D) BDE-103, E) CB-207, F) BDE-156 and G) BDE-181. 
 
 
3.4.7 Detection limits 
 The detection limits of POPs from the validation study were estimated by extrapolating the 
concentration that would result in a signal to noise ratio (S/N) of 3. The S/N ratio was 
measured in the lowest spiked level for all compounds except the PCBs analyzed in EI mode, 
where a non-spiked horse serum sample was used. Estimated limits of detection (LODs) are 
outlined in Table 11. 
 
Table 11. Estimated LODs for compounds from the validation study. 
Compounds S/N Concentration 
(pg/g serum) 
LOD 
(pg/g serum) 
BDE-28 8.0 1.29 0.5 
BDE-37 6.7 1.44 0.6 
BDE-47 9.8 5.79 1.8 
BDE-85 11 1.24 0.3 
BDE-99 14 2.48 0.5 
BDE-100 5.5 1.18 0.6 
BDE-119 4.5 1.09 0.7 
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Table 11. Continued 
   
Compounds S/N Concentration 
(pg/g serum) 
LOD 
(pg/g serum) 
BDE-138 11 1.08 0.3 
BDE-153 19 1.11 0.2 
BDE-154 13 1.22 0.3 
BDE-183 5.9 1.22 0.6 
BDE-209 149 45.4 0.9 
PeBP 7.0 1.71 0.7 
TBBP-A 8.0 2.94 1.1 
HCBa 23 19.0 2.5 
CB-18a 5.2 97.0 56 
CB-28a 90 418 14 
CB-52a 12 96.0 24 
CB-66a 16 87.0 16 
OCS 18 2.70 0.5 
CB-74 3.1 49.0 47 
CB-81 39 3.92 0.3 
CB-99 5.4 21.0 12 
CB-101 61 116 5.7 
CB-105 54 12.0 0.7 
CB-110 15 70.0 14 
CB-114 43 3.10 0.2 
CB-118 477 44.0 0.3 
CB-123 33 3.29 0.3 
CB-128 18 7.02 1.2 
CB-138 89 21.0 0.7 
CB-153 234 35.0 0.4 
CB-156 80 4.00 0.2 
CB-157 78 2.54 0.1 
CB-167 158 3.24 0.1 
CB-170 112 4.38 0.1 
CB-180 217 6.69 0.1 
CB-183 132 4.36 0.1 
CB-187 194 5.87 0.1 
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Table 11. Continued    
Compounds S/N Concentration 
(pg/g serum) 
LOD 
(pg/g serum) 
CB-189 38 2.37 0.2 
CB-194 158 2.90 0.1 
CB-139 139 3.04 0.1 
a These compounds were determined in EI mode. 
 
3.4.8 Native concentrations of POPs in horse serum used for validation 
The native concentration of POPs in non-spiked serum samples was investigated. The results 
are illustrated in Figure 12 and 13. The level in Figure 12 and 13 illustrates the sum of native 
concentrations in the horse serum and contributions from air, sorbents etc., this additional 
contribution can be measured by procedural blanks. By evaluating and correcting for the 
procedural blanks it was found that the main contribution did not come from the serum, but 
from air or during the sample preparation. The congeners that were found to be present in 
considerable amounts in the horse serum when correcting for the procedural blank were CB-
99, CB-114 and CB-138. A chromatogram of a procedural blank for PBDEs is shown in 
Figure 14. 
 
 
 
Figure 14. Chromatogram of PBDEs found in a procedural blank. The numbers and letters 
corresponds to the following compounds: 1) BDE-47, 2) BDE-99, A) BDE-18, B) BDE-51, C) 
C13BDE-77, D) BDE-103, E) CB-207, F) BDE-156 and G) BDE-181. 
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 Figure 12. Native concentrations of PBDEs and phenols found in non-spiked horse serum (n=3). 
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Figure 13. Native concentrations of PCBs found in non-spiked horse serum (n=3). The PCBs were 
determined in CI mode. 
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3.5 Time-trend and age trend study performed on pooled serum samples from Norway. 
The method described above was used for the analysis of BFRs and PCBs in 21 pooled serum 
samples from the general population of Norway (section 2.2.2). In this study, the recovery of 
the ISTDs were in the range of 70-89% for the PBDEs with mean recovery of 80%, the RSDs 
were in the range of 8-17% with mean RSD of 12%. The recovery of the ISTDs used for the 
PCBs were in the range of 62-73% with mean recovery of 65%. The RSD was in the range of 
8-11% with mean RSD of 9%. TBCr used as ISTD for TriBP and PeBP could not be correctly 
quantified because of a co-eluting compound. CtriBBP-A, the ISTD for TBBP-A had a 
recovery of 75%, with RSD of 16%. These recoveries were in close agreement with the 
results from the validation, except for CtriBBP-A where a higher recovery was obtained. 
To assess the quality of the quantification in this study, samples form an interlaboratory 
comparison (section 2.2.3) were extracted and analyzed. Six PCB congeners (IUPAC No. 28, 
118, 138, 153, 170 and 180) were calculated, and the results were compared with assigned 
values from the interlaboratory comparison. The accuracy of the control samples was in the 
range of 83-111%, with RSD in the range of 0.7-4%, except for CB-28, which gave very 
erroneous results. The reason for this is probably that the samples were analyzed in CI mode, 
which gives a very low response for this congener. 
Concentrations of POPs and additional information concerning the serum pools are given in 
appendix Table D1. When looking at the serum pools from men in the age group 40-50 years, 
the serum concentration of seven PBDE congeners (IUPAC No. 28, 47, 99, 100, 153, 154 and 
183) increased from 1977 (0.61 ng/g lipids) to 1998 (4.85 ng/g lipids), after 1998 there seems 
to be a small decrease or a stabilization and the concentration varies between 3.78 ng/g lipids 
and 4.62 ng/g lipids (Figure15). In the serum pool from 2002 elevated levels are observed, 
5.75 ng/g lipids. The reason for this is unknown, but when comparing with men in the age 
group 25-59 years (3.32 ng/g lipids) in the age-trend study (Figure 17) the high levels found 
in the 2002 pool seems erroneous. The main PBDE congeners, found in all samples, were 
BDE-47 and BDE-153. The main PCB congeners were CB-138, CB-153 and CB-180. Closer 
studies of BDE-47 and BDE-153, revealed an increase in the relative amount of BDE-153 
from the early 1990s, were the contribution from BDE-153 was 18% of total PBDE (sum of 
seven), to 2003 where the contribution was 38%. In the most recent serum pools, the 
contribution from BDE-47 and BDE-153 are approximately the same. The reason for this 
change in PBDE-pattern might be the change in use of technical mixtures of PBDE, (section 
1), or differences in the accumulation potential of BDE-47 and BDE-153. 
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Time-trend study of PBDEs
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Figure 15. The sum of 7 PBDEs in ng/g lipids in pooled serum samples from Norway from 1977 to 
2003. Incorporated in the figure are results from a similar study performed by Thomsen et al. [19], 
marked with an x. The samples from 1977 and 1977x are from the same pool, but the samples from 
1999 and 1999x are from two different pools. 
 
Elevated levels are also seen in the pool from 1991, the reason for this is unknown, but the 
pool might contain serum from several persons with high PBDE levels. In a study performed 
by Thomsen et al. [19], the sum of six PBDEs were used (IUPAC No. 28, 47, 99, 100, 153 
and 154), see Figure 15. Thomsen et al. found BDE-154 in all sample pools except the oldest 
from 1977. In the present study BDE-154 was only detected in three sample pools (1991, 
1997 and 1999). This can be explained by the fact that PBB-153 co-eluted with BDE-154 on 
the column used by Thomsen et al., this was not the case in the present study. 
The time-trend of PCBs was also investigated using the same serum pools. Here the opposite 
trend was observed, with a decrease in the sum of five PCBs (IUPAC No. 101, 118, 138, 153 
and 180) from 1977 to 2003, (665 ng/g lipids to 176 ng/g lipids) (Figure 16). Declining levels 
of PCB have previously been reported [20;21;59]. 
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Figure 16. The sum of 5 PCBs in ng/g lipids in pooled serum samples from Norway from 1977 to 
2003. 
 
The level of CB-153 is about 46 times higher than the level of BDE-47 in the serum pool 
from 2003. This result is in agreement with pervious work, where the level of CB-153 was 
found to be 55 times higher than the level of BDE-47 in breast milk samples from Sweden, in 
2000 [60]. 
An age-trend study of PCBs and PBDEs was performed on pooled serum samples from 2002. 
The PBDE concentration in the serum samples from the age groups 0-4 years (10.4 ng/g 
lipids) and 5-14 years (6.18 and 5.45 ng/g lipids for females and males respectively) was 
elevated compared to the other age groups, see Figure 17. As previously stated, food is 
regarded as a major source for human exposure to BFRs, and BFRs have been reported in 
breast milk [15;18;61] which is the main food source for small children. Prenatal exposure 
might also contribute to the elevated levels seen in infants, similar concentrations to that 
found in human milk have been reported in placenta [62]. Air and dust may also be an 
important contribution source. Young children are particularly vulnerable to contaminants 
found in dust as they are in close contact with floors and dusty surfaces, and small children 
often put hands and objects in their mouths. The exposure of PBDEs through inhalation has 
been estimated to be 7% of total exposure (93% from diet) [9]. Levels of PBDEs have been 
reported in dust from the US and Europe [63;64]. 
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In the study by Thomsen et al. [19], the serum concentration was higher in the male pools, 
compared to female pools, for people above 25 years and older (Figure 17). This gender 
difference was much smaller in the present study. The reason for this is unknown. 
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 Figure 17. Two age-trend studies are compared. In 1998 the sum of six PBDEs was calculated, in 
2002 the sum of seven PBDEs was used. In the age group 5-14 years only one pool was analyzed in 
1998. Abbreviations: f; female, m; male. 
 
The concentration of PBDEs in the pooled serum samples from 2002 have decreased 
compared to the study from 1998 (Figure 17), this is in agreement with the results from the 
time-trend study (Figure 15). The reason for the increase in concentration in the age group 5-
14 years might be due to exposure during the 1990s, when the levels have been shown to be 
high (Figure 15). The children represented in the age group 0-4 years in the study by 
Thomsen et al. will in the present study be in the age group 5-14 years, this might be the 
reason for the increased levels. 
In the age-trend study of PCBs, the sum of five PCBs increased from 97.5 ng/g lipid in the 
age group 0-4 years to 308 ng/g lipid and 353 ng/g lipid for women and men in the age group 
>60 respectively (Figure 18). These results are in agreement with the fact that PCBs 
accumulate over time.  
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Figure 18. Age-trend study of the sum of five PCBs in pooled serum samples.  
 
Chromatograms of a pooled serum sample (1998) and a procedural blank are illustrated in 
Figures 19 and 20. In the serum pool from 1998 (Figure 19) a peak is seen with retention time 
21.36 minutes, this compound was identified as a nona-PCB and were found in all the serum 
pools. 
 
 
Figure 19. A chromatogram of a pooled serum sample from 1998. The numbers and letters 
corresponds to the following compounds: 1) BDE-47, 2) BDE-100, 3) BDE-99, 4) BDE-153, 5) BDE-
 49 
Chapter 3  Results and discussion 
183, A) BDE-18, B) BDE-51, C) C13BDE-77, D) BDE-103, E) CB-207, F) BDE-156 and G) BDE-
181. 
  
Figure 20. A chromatogram of a procedural blank extracted at the same time as the serum pools. 1) 
BDE-47, 2) BDE-99, A) BDE-18, B) BDE-51, C) C13BDE-77, D) BDE-103, E) CB-207, F) BDE-156 
and G) BDE-181. 
 
 
TBBP-A was also determined in the serum pools. Prior to derivatization, the sample extracts 
were analyzed for native methylated derivatives of TBBP-A. Tetrabromobisphenol A 
dimethyl ether (methylated TBBP-A) was observed in all the serum pools. Further 
investigations revealed strong matrix effects in the analysis prior to derivatization, so the 
native concentrations could not be corrected for with the use of external standards. The 
following values given for TBBP-A are therefore the sum of TBBP-A (native) and 
methylated TBBP-A. 
TBBP-A was found in all serum pools from 1982-2003. The concentration ranged from 0.01-
0.66 ng/g lipids, with an average concentration of 0.40 ng/g lipids. Elevated levels were 
observed in the 1991 serum pool (1.01 ng/g lipids) and the 2000 serum pool (0.88 ng/g lipids) 
(Results not shown). In the different age group pools from 2002 the concentration of TBBP-A 
was in the range of 0.01-1.99 ng/g lipids. In one sample pool (men, 25-59 years) a very large 
peak was observed for TBBP-A, this peak could not be correctly quantified with the 
calibration curves used in this study. 
BDE-209 was also detected in all serum pools. The sample pools from 1977 and 1982 are not 
included here, due to poor recovery. The reason for this is probably that these samples were 
more viscous and therefore difficult to work with due to old age and the fact that these 
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samples have been frozen and thawed several times. The concentration of BDE-209 in the 
serum pools from 1988 to 2003 was in the range of 5.28-36.7 ng/g lipids. The highest 
concentration of BDE-209 was found in the serum pool from 2000. The average 
concentration over the entire period was 11.0 ng/g lipids. In the age group pools from 2002 
the concentration of BDE-209 was in the range 6.74-20.7 ng/g lipids. The average 
concentration in all the age group pools was 10.0 ng/g lipids. The highest concentration was 
observed in the age pool from female’s age 15-24 years. Similar trends as that seen for the 
other PBDEs was not observed for BDE-209 or TBBP-A, but the two compounds were 
detected in almost all the samples. All values for BDE-209 and TBBP-A are given in 
appendix, Table D1. 
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4.  Conclusion 
The automated method developed for determination of POPs in human serum is fast 
compared to traditional manual SPE, simple and consumes low amounts of solvent compared 
to liquid-liquid extraction. The automatic unit is capable of working around the clock, and 
with the SPE method outlined in this study up to 24 serum samples can be extracted within 24 
hours. For the additional clean-up step, which is less time consuming, up to 96 extracts can be 
cleaned-up within the same time period.  
The method was validated, and the accuracy and precision was found satisfactory for most 
compounds. The phenols, BDE-209 and some of the PCBs were difficult, mainly due to high 
background levels (contributions from air, sorbents etc.). Detection limits were obtained in 
the range of 0.2-1.8 pg/g serum for the PBDEs and phenols, the PCB and OCs had LODs in 
the range of 0.1-56 pg/g serum. The linearity of the method was determined and correlation 
factors (r) of 0.9981 or better were found.   
The method has been used to investigate the levels of PBDEs and PCBs in 21 pooled serum 
samples form the general Norwegian population and was found suitable for this application.  
This fast and simple multi-method enables us to perform cost-effective, large-scale analysis-
series, which are of utmost importance with respect to further investigations on POPs related 
to e.g. human exposure characterizations or possible health effects. 
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6.  APPENDIX 
 
A.  Solvent exchange 
The presence of nonpolar solvents, used in the spiking solutions, was found to reduce the 
recovery of the polybrominated diphenyl ethers (PBDEs), especially the most lipophilic 
compounds. A change in solvent to a more polar solvent was therefore performed. 
 
Procedure 
Empty tubes (15 mL, screw cap) were spiked with internal standard solutions (total volume 
150 µL). A solvent exchange was performed by adding 200 µL of ethanol to each tube, 
whirlmixing and carefully evaporating on a labline to a total volume of 200 µL. Samples 
were then prepared according to section 2.7. 
 
Results/discussion 
The solvent exchange resulted in an increase in recovery of about 10% for the PBDEs, Figure 
A1. 
The effect of solvent exchange on PBDEs.
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Figure A1. The effect of performing a solvent exchange is illustrated for PBDEs (n=4). 
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The solvent exchange was therefore applied during method development and method 
validation. 
After the validation, section 3.4, it was concluded that the solvent exchange did not have a 
positive effect on the PCBs. Volatile compounds were lost during evaporation, section 3.4.4. 
A solvent exchange was therefore not performed in the time-trend and age-trend study of 
POPs, section 3.5. 
Since no solvent exchange were performed on the samples from the time-trend and age-trend 
study, several sonication steps were incorporated in the sample preparation to improve the 
mixing of the ISTD solutions with the serum.  
 
 
B.  Spiking solutions / Internal standards 
All spiking solutions are listed in section 2.3.  Spiking levels used in the method validation 
are listed in Table 9. Internal standard solutions added to the serum pools are outlined in 
Table B1. 
 
Table B1. ISTDs added to the serum pools. 
Volume added Internal standards Concentration 
30 µL PBDEs 2.5 pg/µL, 25 pg/µL BDE-209 
30 µL Phenols 1 pg/µL TBCr, 3 pg/µL CtriBBP-A 
50 µL PCBs 20 pg/µL 
40 µL Mono-ortho PCBs 5 pg/µL 
Total volume added to each sample: 150 µL. 
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Compounds Internal standards  
(PCB, OCs) 
Compounds Internal 
standards 
(PBDE) 
Compounds Internal 
standards 
(Phenols) 
HCB 13C-HCB BDE-28 
BDE-37 
BDE-18 TriBP 
PeBP 
TBCr 
CB-18 
CB-28 
13C-CB-28 BDE-47 BDE-51 TBBP-A CtriBBP-A 
CB-52 13C-CB-52 BDE-99 BDE-77 
OCS 
CB-66 
CB-74 
CB-81 
CB-99 
CB-101 
CB-110 
13C-CB-101 BDE-85 
BDE-100 
BDE-119 
BDE-153 
BDE-154 
BDE-103 
CB-105 13C-CB-105 BDE-138 BDE-156 
CB-114 13C-CB-114 BDE-183 BDE-181 
CB-118 13C-CB-118 BDE-209 13C-BDE-209 
CB-123 13C-CB-123 
CB-138 13C-CB-138 
CB-153 13C-CB-153 
CB-156 13C-CB-156  
CB-157 13C-CB-157 
CB-128 
CB-167 
13C-CB-167 
CB-170 13C-CB-170 
CB-180 
CB-183 
CB-187 
13C-CB-180 
CB-189 13C-CB-189 
CB-194 13C-CB-194 
CB-209 13C-CB-209 
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The concentration of PBDEs, PCBs and TBBP-A found in the pooled serum samples, section 
2.2.2, are listed in Table D1. 
 60 
C. Internal standards 
An overview of internal standards used in all experiments is listed in Table C1. 
 
Table C1. An overview of compounds and their respective internal standards. 
 
 
 
D. Raw data from the time-trend and age-trend study. 
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Table D1. Serum concentrations of PBDEs, PCBs and TBBP-A in ng/g lipids, pooled serum samples. 
Abbreviations: f, fema , zed les; m  males; Nd, not detected; - not analy  
Serum pool Fat 
% 
N  BDE-
28 
BDE-
47 
BDE-
99 
BDE-
100 
BDE-
153 
BDE-
154 
BDE-
183 
BDE-
209 
CB-28 CB-
101 
CB-
118 
CB-
138 
CB-
153 
CB-
180 
TBBP-A 
1977                 0.62 34 Nd 0.49 0.11 0.01 0.01 Nd Nd Nd 174 50.8 53.8 127 251 183
1977x               0.62 34 Nd 0.25 0.09 Nd 0.10 Nd - - - - - - - -
1981                 0.67 17 0.10 0.32 0.13 0.08 0.18 Nd Nd - - - - - - - Nd
1982                 0.72 18 Nd 0.84 0.20 0.13 0.18 Nd 0.02 Nd 92.1 10.9 46.6 146 290 218 0.06
1986                0.74 24 Nd 0.41 0.13 0.12 0.14 Nd Nd - - - - - - - 0.44
1988                 0.63 23 Nd 0.77 0.26 0.14 0.27 Nd 0.05 7.43 Nd 9.20 33.0 91.8 179 137 0.53
1990           0.68 20 0.07 0.89 0.24 0.13 0.27 Nd Nd - - - - - - - 0.42
1991                 0.72 19 0.16 2.83 0.65 0.32 0.92 0.01 0.14 5.28 Nd 8.51 19.9 60.1 122 97.5 1.01
1994                 0.68 30 0.07 1.83 0.48 0.31 0.65 Nd 0.06 6.61 Nd 5.60 15.4 52.2 108 95.5 0.66
1995           0.69 19 0.14 1.40 0.33 0.32 0.52 Nd Nd - - - - - - - 0.59
1997                 0.61 14 0.04 2.35 0.56 0.36 1.09 0.04 0.09 4.69 Nd 6.82 11.8 44.1 106 99.6 0.45
1998                 0.66 20 0.06 2.25 0.63 0.36 1.20 Nd 0.34 15.0 Nd 6.91 13.4 47.3 107 89.7 0.16
1999                 0.72 20 0.18 1.72 0.53 0.27 1.16 0.07 0.15 10.2 Nd 6.07 12.1 41.5 91.5 76.1 0.41
1999x         0.65 29 0.24 1.50 0.31 0.35 0.59 0.35 - - - - - - - -  
2000                 0.60 20 0.05 1.77 0.68 0.44 1.55 Nd 0.14 36.7 Nd 7.30 11.6 39.6 96.1 83.5 0.88
2001                 0.62 20 0.25 1.46 0.35 0.27 1.52 Nd 0.13 6.18 Nd 5.77 9.63 31.2 71.0 63.9 0.06
2002                 0.64 20 0.11 2.80 0.87 0.38 1.37 Nd 0.22 7.60 Nd 6.15 8.62 26.3 60.7 53.1 0.08
2003                 0.73 20 0.03 1.51 0.40 0.29 1.42 Nd 0.12 10.1 Nd 6.08 10.1 32.7 69.4 57.5 0.06
0-4 years                 0.51 29 0.08 4.57 2.27 1.02 1.67 0.09 0.06 8.70 Nd 8.29 6.08 19.4 40.1 23.6 0.19
5-14f years                 0.55 20 0.09 2.71 1.27 0.70 1.38 0.07 0.20 11.7 Nd 7.86 7.91 18.1 40.1 24.2 0.02
5-14m years                 0.54 20 0.08 2.18 0.76 0.49 1.85 Nd 0.05 10.3 Nd 9.10 5.21 14.2 31.0 18.2 0.01
15-24f years                 0.57 20 0.08 1.30 0.39 0.28 0.95 Nd 0.11 20.7 Nd 6.75 4.50 11.7 23.4 13.8 0.15
15-24m years                 0.47 20 0.08 1.32 0.41 0.21 1.46 Nd 0.12 6.74 Nd 8.45 4.65 13.7 33.6 25.5 0.44
25-59f years                 0.67 20 0.04 1.56 0.35 0.30 0.77 Nd 0.02 7.64 Nd 5.79 7.96 20.1 42.7 33.6 0.10
25-59m years                 0.61 20 0.09 1.25 0.34 0.20 1.28 Nd 0.18 6.83 Nd 5.16 6.10 23.5 52.4 43.9 Nd
>60f years 0.75 20                0.09 1.27 0.38 0.28 0.91 Nd 0.06 9.68 Nd 4.65 25.3 59.8 123 95.4 1.99
>60m years                 0.69 20 0.09 1.18 0.28 0.29 1.09 Nd 0.06 7.39 Nd 6.00 22.4 60.0 140 124 0.28
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